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Recently,  endoscopic ultrasonography (EUS)-guided ethanol ablation for small pancreatic neuroendo-
crine tumors (p-NETs) has been reported.  However,  the eﬃcacy and safety of the technique remain 
unclear.  We have launched a prospective pilot study of EUS-guided ethanol ablation for p-NETs.  The 
major eligibility criteria are the presence of a pathologically diagnosed grade (G) 1 or G2 p-NET,  a 
tumor size of 2cm,  and being a poor candidate for surgery.  A total of 5 patients will be treated.  The 
primary endpoint will be the complete ablation rate at 1 month after treatment.
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P ancreatic neuroendocrine tumors (p-NETs) are fairly rare,  and they account for 1-2  of primary 
pancreatic malignancies [1].  However,  the incidence 
of p-NETs has increased substantially because of the 
widespread use of advanced endoscopic and radiologi-
cal imaging techniques [2].  The 5-year overall sur-
vival rates range from 30  for nonfunctional neuroen-
docrine tumors to 97  for benign insulinomas [3].
　 For patients with resectable p-NETs that are 
＞2cm,  surgical resection is the standard of care [4].  
On the other hand,  there is no survival beneﬁt associ-
ated with surgery for those with nonfunctional small 
p-NETs that are＜2cm [5],  and the beneﬁt of sur-
gery must be balanced against operative morbidity and 
mortality.  Pancreatic resection,  especially pancreati-
coduodenectomy (PD),  has been associated with high 
rates of major complications,  including death [6,  7].  
The PD mortality and major complications rates are 
about 4  and 15 ,  respectively [6].
　 Recently,  endoscopic ultrasonography (EUS)-guided 
ethanol ablation has been proposed for the treatment 
of patients with small p-NETs who refuse surgery or 
are poor surgical candidates [8,  9].  Levy et al.  [8] 
reported that EUS-guided ethanol ablation for insuli-
nomas was technically feasible and safe,  and symptom-
atic improvement was achieved in all 8 of their 
patients.  Park et al.  [9] reported that after a single 
session of ethanol ablation therapy,  54  (8/13) of 
their patients showed complete responses at the 
3-month radiologic imaging assessments and that 
adverse events had occurred in 27  (3/11) of the 
patients who had small p-NETs that were＜2cm in 
diameter.
Acta Med.  Okayama,  2016
Vol.  70,  No.  4,  pp.  313-316
CopyrightⒸ 2016 by Okayama University Medical School.
Clinical Study Protocol http ://escholarship.lib.okayama-u.ac.jp/amo/
Received June 6,  2016 ; accepted July 13,  2016.
＊Corresponding author.  Phone : ＋81-86-225-5991; Fax : ＋81-86-235-7219
E-mail : matsumotokazuyuki0227@yahoo.co.jp (K. Matsumoto)
Conﬂict of Interest Disclosures: No potential conﬂict of interest relevant 
to this article was reported.
　 However,  these studies were not prospective stud-
ies,  and the eﬃcacy and safety of this procedure 
remain unclear.  Indeed,  the complete ablation rate is 
inadequate.  Therefore,  we were prompted to launch 
the current trial to determine whether planned repeat 
ethanol ablation sessions might improve the complete 
ablation rate and,  hence,  to determine whether EUS-
guided ethanol ablation therapy could be a very useful 
and less invasive therapy for patients with small 
p-NETs who refuse surgery or are poor candidates for 
surgery.
Endpoints
　 Primary and secondary endpoints and other 
evaluations. The primary endpoint will be the 
complete ablation rate at 1 month after the ﬁrst treat-
ment session.  The complete ablation rate will be 
deﬁned as the ratio of patients in whom any enhanced 
areas within the tumors disappear on contrast-
enhanced-computed tomography (CE-CT) images after 
1 month of the ﬁrst discharge following treatment.  
The CE-CT images will be reviewed by an expert 
radiologist and an independent expert gastroenterolo-
gist.  The secondary endpoints will be the adverse 
events associated with the procedure,  the procedure 
time,  the number of ethanol injections administered,  
the volume of ethanol injected,  the total number of 
sessions,  the number of days spent in hospital,  the 
incidence of diabetes after treatment,  the recurrence 
rate,  and the retreatment results.  For patients with 
functional p-NETs,  the rate of symptom improvement 
and changes in the serum hormone levels after treat-
ment will be evaluated.  The secondary endpoints will 
be prospectively evaluated from the patientsʼ records.  
We will also establish a safe evaluation committee,  
which will comprise 3 additional doctors who are not 
associated with the study,  to determine whether the 
study should continue when severe adverse events 
occur,  which will include death,  life-threatening 
complications,  severe pancreatitis requiring intensive 
care unit management and surgical intervention and,  
thus,  a signiﬁcant extension of the hospitalization 
period,  and persistent or a signiﬁcant disability of a 
patientʼs general functions.
Eligibility Criteria
　 All of the patients who meet the main inclusion and 
exclusion criteria,  which are listed in Table 1,  will be 
invited for screening.  The major eligibility criteria 
are the presence of a pathologically diagnosed grade 
(G) 1 or G2 p-NET,  a tumor size of 2cm,  and being 
a poor candidate for surgery.
　 Study setting. We have launched a single-arm,  
prospective,  nonrandomized,  noncomparative,  open-
label,  single-center,  pilot study.
　 Ethical considerations. The investigators 
must obtain written informed consent from the patients 
before any screening takes place or inclusion proce-
dures are considered.  This study will be conducted in 
a manner that complies with the principles of the 
Declaration of Helsinki.  The studyʼs protocol has been 
approved by the institutional review board of our 
hospital (approval number: 1510-003,  UMIN Trial 
registration number: 000018834).
Treatment Methods
　 Endoscopic ultrasonography-guided interven-
tion and study flow. Fig.  1 presents the studyʼs 
ﬂow chart.  For the ﬁrst treatment we will slowly 
advance the 22 G or 25 G ﬁne needle aspiration (FNA) 
needle into the center of the tumor under real-time 
EUS,  then pure ethanol (Mylan Seiyaku Ltd,  Tokyo,  
Japan) will be injected until a hyperechoic blush 
extends to the tumorsʼ margins.  Blood testing at 2h 
postoperatively,  and on postoperative day (POD) 1 
and POD 3 will evaluate the secondary endpoints.  
CE-CT performed on PODs 3-5 will evaluate tumor 
viability and the adverse events.  When the CE-CT 
images show enhancement,  1 session of EUS-guided 
ethanol reablation therapy will be scheduled between 
POD 3 and POD 5 of the same hospitalization period.
　 For EUS-guided ethanol reablation therapy,  con-
trast-enhanced harmonic-EUS (CEH-EUS) imaging 
will conﬁrm the tumorʼs viable regions using perﬂubu-
tane (Daiichi-Sankyo Company,  Limited,  Tokyo,  Japan) 
as the contrast agent.  The methods used will be the 
same as those used previously.
　 Follow-up CE-CT imaging at 1 month after dis-
charge will evaluate the tumorʼs viability and the 
adverse events.  Complete ablation will be deﬁned as 
the absence of enhanced areas within the tumor on the 
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Table 1　 Patient eligibility criteria
Inclusion criteria
　A diagnosis of a p-NET (G1 or G2) that was conﬁrmed by the pathology of a needle specimen obtained by EUS-FNA (WHO 2010 clas-
siﬁcation)
　Poor surgical candidate (ASA grade III) or refusal of surgery
　Tumor diameter 2cm according to CE-CT
　A p-NET diagnosed as a nonfunctional tumor or an insulinoma
Exclusion criteria
　Severe drug allergy history
　Allergy to contrast media
　Allergy to ethanol
　Tumor not visualized or could not be punctured using EUS
　Diagnosed with an NEC based on a needle specimen obtained by EUS-FNA (WHO 2010 classiﬁcation)
　Tumor located near the main pancreatic duct
　PT 50% or INR 1.5
　PLT 50×109/L
　eGFR 30mL/min
　Administered 2 antithrombotic agents
　Performance status 2
　Estimated poor prognosis of＜3 years
　Age＜20 years
　Patient did not provide informed consent
　Patients who were judged as being inappropriate by the chief medical examiner
p-NET,  pancreatic neuroendocrine tumor; G,  grade; EUS,  endoscopic ultrasonography; EUS-FNA,  endoscopic ultrasonography-ﬁne 
needle aspiration; NEC,  neuroendocrine carcinoma; ASA,  American Society of Anesthesiologists; WHO,  World Health Organization;  
CE-CT,  contrast-enhanced-computed tomography; PT,  prothrombin time; INR,  international normalized ratio; PLT,  platelet; eGFR,  
estimated glomerular ﬁltration rate.
Fig. 1　 The studyʼs ﬂow chart.  EUS,  endoscopic ultraso-
nography; CE-CT,  contrast-enhanced-computed tomogra-
phy.
arterial or the portal venous phase images.  Incomplete 
ablation will be deﬁned as the presence of enhanced 
areas within the tumor.  When incomplete ablation has 
occurred,  the protocol for a second treatment will be 
followed.  Three-monthly follow-up CE-CT imaging 
will be performed on patients who have achieved 
complete ablations at the ﬁrst follow-up assessment.  
Enhanced areas found following complete ablation will 
be deﬁned as recurrences,  and the protocol for a 
second treatment will be followed.  Blood testing at 1 
month after discharge and every 3 months thereafter 
will evaluate the secondary endpoints.  The blood from 
the patients who have functional p-NETs will undergo 
serum hormone assays.  Patients will be followed up 
for 1 year after the ﬁrst treatment.  The ﬁrst and 
second treatment protocols will be the same.  If incom-
plete ablation occurs after the second treatment,  we 
will consider other treatments.
Statistical Consideration
　 We have determined that the sample size should be 
5,  because p-NETs are fairly rare,  accounting for 
1-2  of the primary pancreatic malignancies [1].  
During the past 4 years,  26 patients have presented 
at the participating hospitals with small p-NETs that 
measure＜2cm.  Given the incidence of these tumors 
at the participating hospitals and the eligibility crite-
ria,  we anticipate that 5 patients will present with 
p-NETs every 2 years.
References
 1. Yao JC,  Eisner MP,  Leary C,  Dagohoy C,  Phan A,  Rashid A,  
Hassan M and Evans DB: Population-based study of islet cell car-
cinoma.  Ann Surg Oncol (2007) 14: 3492-500.
 2. Modlin IM,  Oberg K,  Chung DC,  Jensen RT,  de Herder WW,  
Thakker RV,  Caplin M,  Delle Fave G,  Kaltsas GA,  Krenning EP,  
Moss SF,  Nilsson O,  Rindi G,  Salazar R,  Ruszniewski P and 
Sundin A: Gastroenteropancreatic neuroendocrine tumours.  Lancet 
Oncol (2008) 9: 61-72.
 3. Oberg K and Eriksson B: Endocrine tumours of the pancreas.  Best 
Pract Res Clin Gastroenterol (2005) 19: 753-781.
 4. Falconi M,  Plockinger U,  Kwekkeboom DJ,  Manfredi R,  Korner M,  
Kvols L,  Pape UF,  Ricke J,  Goretzki PE,  Wildi S,  Steinmuller T,  
Oberg K and Scoazec JY: Well-diﬀerentiated pancreatic nonfunc-
tioning tumors/carcinoma.  Neuroendocrinology (2006) 84: 196-
211.
 5. Bettini R,  Partelli S,  Boninsegna L,  Capelli P,  Crippa S,  
Pederzoli P,  Scarpa A and Falconi M: Tumor size correlates with 
malignancy in nonfunctioning pancreatic endocrine tumor.  Surgery 
(2011) 150: 75-82.
 6. Pecorelli N,  Balzano G,  Capretti G,  Zerbi A,  Di Carlo V and 
Braga M: Eﬀect of surgeon volume on outcome following pancre-
aticoduodenectomy in a high-volume hospital.  J Gastrointest Surg 
(2012) 16: 518-523.
 7. Nathan H,  Cameron JL,  Goodwin CR,  Seth AK,  Edil BH,  
Wolfgang CL,  Pawlik TM,  Schulick RD and Choti MA: Risk fac-
tors for pancreatic leak after distal pancreatectomy.  Ann Surg 
(2009) 250: 277-281.
 8. Levy MJ,  Thompson GB,  Topazian MD,  Callstrom MR,  Grant CS 
and Vella A: US-guided ethanol ablation of insulinomas: a new 
treatment option.  Gastrointest Endosc (2012) 75: 200-206.
 9. Park do H,  Choi JH,  Oh D,  Lee SS,  Seo DW,  Lee SK and Kim 
MH: Endoscopic ultrasonography-guided ethanol ablation for small 
pancreatic neuroendocrine tumors: results of a pilot study.  Clin 
Endosc (2015) 48: 158-164.
316 Acta Med.  Okayama　Vol.  70,  No.  4Matsumoto et al.
